Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571300 | 0.92 | GSR (0.33) | GSRTXNRD1CYSLTR2CYSLTR1 | |
| SCHEMBL25448015 | 0.79 | GPR84 (0.35) | GSRTXNRD1KDM4ENPSR1L3MBTL1 | |
| SCHEMBL23920665 | 0.78 | GPR84 (0.38) | GSRTXNRD1KDM4ENPSR1L3MBTL1 | |
| SCHEMBL23920637 | 0.76 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL15940594 | 0.76 | PDCD1LG2 (0.30) | — | |
| SCHEMBL8550099 | 0.70 | PDE2A (0.38) | L3MBTL1 | |
| SCHEMBL22215351 | 0.69 | L3MBTL1 (0.36) | KDM4EL3MBTL1 | |
| SCHEMBL22260436 | 0.69 | CYSLTR2 (0.38) | KDM4EL3MBTL1CYSLTR2CYSLTR1 | |
| SCHEMBL23059309 | 0.69 | L3MBTL1 (0.36) | KDM4ENPSR1L3MBTL1 | |
| SCHEMBL18672329 | 0.68 | KCNH2 (0.40) | KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | GSR 4015/4885TXNRD1 1159/4885KDM4E 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.